Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. In addition, 66.7%

Clinical Trials 40

Clinical Trials Safety Data Patients 40

Cannabis Law Report

JULY 8, 2021

“Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.” Clomiphene will then be added to the regimen for up to 24 patients to rule out toxicity.

Treatment 98

Treatment Clinical Trials CBD Patients 98

MMJ Recs

JULY 30, 2024

Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Research suggests that cannabinoids may modulate these processes, potentially offering relief from PTSD symptoms.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. I have used it in some of my patients with autism. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. For more information, visit www.silopharma.com. Safe Harbor and Forward-Looking Statements.

Patients 70

Patients Research and Development Clinical Trials Chronic Pain 70

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. Forward-looking statements are only predictions. Investor Relations: Evan Veryard.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. We’ll never know for certain whether this article was intentionally designed to scare potential MMJ patients away.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Highlights from the presentation include: Declining PSA levels in treated patients. Declining circulating tumor cell (CTC) count in treated patients. Phase 2 trial underway. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Puff Puff Post

JULY 8, 2019

She is a seven-time Olympic trials qualifier in three sports: marathon (three), triathlon (three), and swimming (one). When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. Our results need to be replicated in larger studies and clinical trials.

Chronic Pain 109

Chronic Pain Research and Development Clinical Trials THC 109

Puff Puff Post

JULY 8, 2019

She is a seven-time Olympic trials qualifier in three sports: marathon (three), triathlon (three), and swimming (one). When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. Our results need to be replicated in larger studies and clinical trials.

Chronic Pain 108

Chronic Pain Research and Development Clinical Trials THC 108

Cannabis Law Report

JULY 27, 2021

The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

The Joint Blog

JUNE 2, 2020

According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. Adverse events were mostly mild and resolved spontaneously. 9 -THC: 0.5mg, 1mg, or a placebo. ?

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

TheAnswerPage

NOVEMBER 29, 2021

What serious adverse events have been noted in psilocybin clinical trials? The serious adverse events (AE) reported in the psilocybin clinical trial conducted by Compass Pathways occurred in 12 of the 233 patients and included suicidal behavior, suicidal ideation, and intentional self-injury.

Clinical Trials 40

Clinical Trials Events Patients 40

TheAnswerPage

MARCH 11, 2022

In the clinical trials evaluating a purified CBD product (Epidiolex) in epilepsy patients, side effects including sedation, decreased appetite, diarrhea, sleep disturbance, infections, pneumonia, viral infections and weight loss were reported. ” Kirkland AE, Fadus MC et al. Psych Resear. 308 (2022). See the Answer.

Clinical Trials 40

Clinical Trials Epilepsy Events Sleep 40

Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. “I agree with the committee that the preliminary findings from clinical trials — although still in early phases — evaluated by the panel are promising,” the decision’s author said.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

The Joint Blog

APRIL 21, 2020

For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. There is moderate-quality evidence that chronic and acute administration of CBD can improve psychotic symptoms in schizophrenia patients.”

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

MMJ Recs

JULY 11, 2024

Many patients are turning to cannabis for insomnia relief, seeking its potential to improve sleep quality and duration. In this article, we explore the role of medical marijuana in addressing insomnia, examining its effectiveness, safety considerations, legal aspects, and practical considerations for patients and healthcare providers.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Cannabis Law Report

AUGUST 24, 2021

Thus, there is a great need to develop new and effective therapeutics for treating patients. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease and decline rather than only addressing the symptoms.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Project CBD

FEBRUARY 28, 2023

13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e., Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

JUNE 7, 2021

MDMA has also reportedly been used with over 1,000 individuals in clinical trials , with no adverse effects to report. . However, it is known that MDMA is popularly consumed at parties, raves, and any other social events which pair well with the stimulation and if you will, the ‘enlightenment’ associated with MDMA.

Therapy 92

Therapy Treatment Conditions Clinical Trials 92

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Cannabis Law Report

JULY 7, 2021

Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., inhibitors are the most prescribed drugs by revenue globally, at $40 billion per year. Chief Scientific Officer for MyMD. Investor Contact: Robert Schatz. 646) 421-9523. 201-465-8019.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Otherside Farms

JANUARY 14, 2019

While there is a need for more clinical trials on the subject, users and alternative-therapy practitioners worldwide continue to buy cannabis seeds online for healing physical and mental ailments. Here are five popular medicinal uses of cannabis with low concentration of the intoxicating chemical compound tetrahydrocannabinol (THC).

Clinical Trials 49

Clinical Trials Strains Therapy Medicine 49

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide. eslicarbazepine.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Petition for Review.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS). Researchers examined studies that used both natural and synthetic THC and CBD.

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

The Cannigma

DECEMBER 12, 2022

Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.

History 119

History Microdosing Research and Development Clinical Trials 119